Kythera IPO Seeks $86.2M for ATX-101 U.S. Phase III
By Marie Powers
Friday, May 18, 2012
Aesthetic specialist Kythera Biopharmaceuticals Inc. filed an S-1 with the SEC seeking to raise $86.2 million in an initial public offering, with "substantially all" of the net proceeds used to fund U.S. Phase III trials of lead compound ATX-101, according to the filing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.